Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database.
Roberta NosedaFrancesca BedussiClaudio GobbiChiara ZeccaAlessandro CeschiPublished in: Cephalalgia : an international journal of headache (2021)
No specific maternal toxicities, patterns of major birth defects, or increased reporting of spontaneous abortion were found. However, because of the relatively limited number of adverse drug reactions reported and the lack of long-term safety data, continuous surveillance is required in pregnant and lactating women exposed to these drugs.
Keyphrases
- adverse drug
- pregnancy outcomes
- electronic health record
- pregnant women
- dairy cows
- drug induced
- emergency department
- public health
- human milk
- preterm birth
- big data
- heat stress
- birth weight
- metabolic syndrome
- physical activity
- skeletal muscle
- preterm infants
- breast cancer risk
- low birth weight
- cervical cancer screening